Stocks AstraZeneca PLC

More

  • Pfizer's proposed acquisition of Allergan will be one of the biggest tax inversions yet.

  • Nov 23- Pfizer Inc's looming deal to buy Botox maker Allergan Plc for more than $150 billion will cap a record-breaking run for mergers and acquisitions in the healthcare sector, taking the cumulative value of deals in 2015 to more than $600 billion. Pfizer's tax-driven takeover of Allergan, which people familiar with the matter said won board approval on...

  • Nov 23- Pfizer Inc's looming deal to buy Botox maker Allergan Plc for more than $150 billion will cap a record-breaking run for mergers and acquisitions in the healthcare sector, taking the cumulative value of deals in 2015 to more than $600 billion. Pfizer's tax-driven takeover of Allergan, which people familiar with the matter said won board approval on...

  • LONDON, Nov 20- Drug companies have brought a host of expensive new medicines to market in the United States and Europe this year, figures show, another bumper haul for an industry often accused of over-charging. The U.S. Food and Drug Administration has so far approved 38 novel drugs in 2015, more than the 34 that had been cleared by this stage a year ago and just...

  • LONDON, Nov 20- Drug companies have brought a host of expensive new medicines to market in the United States and Europe this year, figures show, another bumper haul for an industry often accused of over-charging. The U.S. Food and Drug Administration has so far approved 37 novel drugs in 2015, more than the 34 that had been cleared by this stage a year ago and just...

  • LONDON, Nov 20- French drugmaker Sanofi and Britain's AstraZeneca said on Friday they had agreed a direct exchange of 210,000 chemical compounds from their respective libraries in a new twist on the drive to boost open innovation. In a bid to increase the number of leads for new medicines, and save both time and money, pharmaceutical companies are experimenting...

  • LONDON, Nov 17- AstraZeneca's new lung cancer pill Tagrisso, which won early U.S. approval on Friday, will cost $12,750 for a month's supply. A company spokeswoman said on Tuesday the wholesale acquisition cost was comparable to other targeted oral lung cancer therapies, such as Pfizer's Xalkori and Novartis' Zykadia. AstraZeneca has previously said it believes...

  • LONDON, Nov 17- AstraZeneca's new lung cancer pill Tagrisso, which won early U.S. approval on Friday, will cost $12,750 for a month's supply. A company spokeswoman said on Tuesday the wholesale acquisition cost was comparable to other targeted oral cancer therapies, including AstraZeneca's Iressa. AstraZeneca has previously said it believes Tagrisso could...

  • Nov 16- Clovis Oncology Inc said the U.S. Food and Drug Administration had asked for additional data on the effectiveness of its lung cancer drug, which could delay an approval for the treatment. Analysts had expected an earlier approval for the drug after a similar treatment from AstraZeneca Plc was approved on Friday, three months ahead of the expected date.

  • Nov 16- Clovis Oncology Inc said the U.S. Food and Drug Administration asked for additional clinical data on the effectiveness of its experimental lung cancer drug, rociletinib, which could delay its approval. The company had a market value of $3.8 billion as of Friday's close. A similar treatment from AstraZeneca, designed for patients whose disease has...

  • LONDON, Nov 13- A new lung cancer pill from AstraZeneca, designed for patients whose disease has worsened after treatment with other therapies, was approved by U.S. regulators on Friday, in a boost for the British drugmaker. Tagrisso, also known as AZD9291, is one of several cancer medicines AstraZeneca hopes will rebuild its sales following patent losses on older...

  • *Potential for technology highlighted at Berlin conference. FRANKFURT/ LONDON, Nov 12- A molecule that carries the recipe for making drugs inside body cells is exciting scientists and investors alike, attracting hundreds of millions of dollars in a scramble for the next promising area of biotechnology. Privately-held CureVac in the university town of...

  • *U.S. sells $24 billion 10- year notes to solid demand. NEW YORK, Nov 10- U.S. Growth and inflation will not increase all that much, "said Phil Guarco, global head of fixed income strategy at J.P. Morgan Private Bank in New York.

  • Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • U.S. stock futures were lower this morning, after Wall Street's worst day since late September. The Dow went back into the red for 2015.

  • MUMBAI, Nov 10- Dr Reddy's Laboratories Ltd, India's second-largest drugmaker by sales, said on Tuesday it had been temporarily barred by a U.S. court from selling its generic form of blockbuster heartburn drug Nexium in the United States. The order was passed by the U.S. district court of Delaware after AstraZeneca, the maker of Nexium, moved a motion objecting to...

  • LONDON, Nov 10- AstraZeneca's experimental lupus drug anifrolumab significantly cut disease activity in a mid-stage clinical trial, boosting hopes for a medicine the company believes could become a $1 billion- a-year seller. AstraZeneca's anifrolumab, which is given intravenously, is designed for patients with moderate to severe lupus and works in a...

  • ORLANDO, Nov 9- Eli Lilly's new diabetes drug Jardiance significantly cut the risk of heart-related death and hospitalization for heart failure in patients with type 2 diabetes who are at high risk for serious heart problems, according to data from a large study presented on Monday. The 3- year trial of more than 7,000 patients caused a sensation in September,...

  • Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.